Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor
about
Origin and proliferation of multiple-drug resistance in bacterial pathogensIdentification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growthAcquired resistance of Mycobacterium tuberculosis to bedaquilineIn vitro activity of rifampicin and verapamil combination in multidrug-resistant mycobacterium tuberculosisIon Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosisSuppression of Protective Responses upon Activation of L-Type Voltage Gated Calcium Channel in Macrophages during Mycobacterium bovis BCG InfectionEfflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosisNew tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeuticsInterplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosisVerapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs.LprG-mediated surface expression of lipoarabinomannan is essential for virulence of Mycobacterium tuberculosis.Latent tuberculosis infection: myths, models, and molecular mechanismsVerapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model.The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents.Reciprocal regulation of reactive oxygen species and phospho-CREB regulates voltage gated calcium channel expression during Mycobacterium tuberculosis infection.Regulation of L-type Voltage Gated Calcium Channel CACNA1S in Macrophages upon Mycobacterium tuberculosis Infection.Statin, calcium channel blocker and Beta blocker therapy may decrease the incidence of tuberculosis infection in elderly Taiwanese patients with type 2 diabetesDosS Is required for the complete virulence of mycobacterium tuberculosis in mice with classical granulomatous lesionsEfficacy of Adjunctive Tofacitinib Therapy in Mouse Models of TuberculosisIn vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis AntibioticsThe antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis.Antimicrobial treatment improves mycobacterial survival in nonpermissive growth conditions.Inflammation and tuberculosis: host-directed therapies.Update in tuberculosis and nontuberculous mycobacterial infections 2013.Totally drug-resistant tuberculosis and adjunct therapies.Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy.Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action.Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from BrazilSuppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis.Bacterial subversion of cAMP signalling inhibits cathelicidin expression, which is required for innate resistance to Mycobacterium tuberculosis.Loperamide Restricts Intracellular Growth of Mycobacterium tuberculosis in Lung Macrophages.[Standard therapy of tuberculosis].Treatment of Tuberculosis. A Historical Perspective.Repurposing and Revival of the Drugs: A New Approach to Combat the Drug Resistant Tuberculosis.Can the addition of verapamil to bedaquiline-containing regimens improve tuberculosis treatment outcomes? A novel approach to optimizing TB treatment.Multifaceted remodeling by vitamin C boosts sensitivity of Mycobacterium tuberculosis subpopulations to combination treatment by anti-tubercular drugs.Verapamil targets membrane energetics in Mycobacterium tuberculosis.Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis.Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis.Efflux Activity Differentially Modulates the Levels of Isoniazid and Rifampicin Resistance among Multidrug Resistant and Monoresistant Mycobacterium tuberculosis Strains.
P2860
Q27023284-C9AE05E2-30D5-4608-B9E4-26C018BCC1D6Q28539975-997248ED-C1FD-488E-B5D5-D6ECEA6696A8Q28540637-B26459CA-DE55-46C1-92F9-18857DD77AC3Q28543447-38EE7C13-6306-42FE-A248-63AC4040B293Q28550401-20D811AD-F23C-4048-8F49-2ECB75BAE6FEQ28554597-21EC2E09-9B9B-4506-8375-DD71BEFFACB9Q28659633-F109F921-241F-40A3-AF79-BB0F2BFA11CAQ30371980-2455BE41-45C9-4023-9679-5411823DED78Q33607162-C384120A-3D41-4D32-84EC-1CC94F0C9A79Q33947806-DC5A649E-46A0-4429-93D3-CBC652696DDDQ34215397-09C32B73-B2A4-40BC-854E-200983EDBA07Q34297816-D2CC1BC7-F45E-4D53-9C3F-4D783CDCD419Q34923159-81B92818-BFF1-41D7-ACF8-D0FCF5750395Q35076888-FC3268AF-AF6C-47C6-B8AF-B09423941B99Q35163267-5A004249-4F64-4FA5-BF2C-88963BBD2720Q35542683-9A608CF8-0A2A-442F-BA31-C4D34D58E434Q35723779-8F5472F0-4E07-4DC6-874A-0615452FF1F7Q35816410-A8AE1417-06AD-446A-84B9-707089212690Q36038705-213F02CE-07C5-49CF-8137-46FBFF58B0F8Q36056408-CE6BC167-D24A-42CA-B0E9-ADDA6E11554EQ37277346-B113FA4A-B9A1-4C27-AA55-65B86064F69DQ37713046-D746C686-4560-47CC-8F6C-E2C463EB69CAQ38203352-F708F9F5-9369-4E62-8A07-1C94AEF60F97Q38204777-13A4B7AA-ADD2-4168-B8BD-0636462FE152Q38210265-93B0B7CE-0FF0-4B58-9490-481115693BE7Q38608754-BBC4B254-8FD5-4C28-8531-0C158ECE4382Q38872058-AA07379D-3DBD-4439-81F6-486925114FC8Q38949658-4258065D-7278-416E-82C0-8BBBA85E8E26Q40070517-AA1B09E5-3A46-48C3-8E44-66C1BBA7DD7FQ40367916-4E70B125-9036-4584-85E0-A81D5EB95BA8Q40596664-6BEA3F19-EC35-49F3-9E64-E2AF35AC887AQ40921842-8B84A973-D5D0-41F5-9A25-631B83B87C26Q46014832-A362E9C1-16AA-4EC6-9C70-53938F60C339Q47429675-4354F9E9-6137-4218-846E-003134999D3FQ48422544-190C72D2-96D0-4072-BFB6-CC2886700243Q48508433-FC6C083D-0F85-4B6A-9DF1-B774D06D3638Q49791987-6150E6DE-EF31-4179-BAE3-6D6B2EA7F291Q50077291-7941FBC4-AB70-4048-9AFC-1964697B6951Q50313165-07FA4F33-C890-40C7-89E6-2EAA04AC0B8EQ53704257-3D2FD0BF-55DE-4352-9BF0-0EE705A7D691
P2860
Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Acceleration of tuberculosis t ...... rapamil as an efflux inhibitor
@en
Acceleration of tuberculosis t ...... apamil as an efflux inhibitor.
@nl
type
label
Acceleration of tuberculosis t ...... rapamil as an efflux inhibitor
@en
Acceleration of tuberculosis t ...... apamil as an efflux inhibitor.
@nl
prefLabel
Acceleration of tuberculosis t ...... rapamil as an efflux inhibitor
@en
Acceleration of tuberculosis t ...... apamil as an efflux inhibitor.
@nl
P2093
P2860
P1476
Acceleration of tuberculosis t ...... rapamil as an efflux inhibitor
@en
P2093
Deepak V Almeida
Mariama C Maiga
Sandeep Tyagi
Shashank Gupta
William R Bishai
P2860
P304
P356
10.1164/RCCM.201304-0650OC
P407
P577
2013-09-01T00:00:00Z